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ABSTRACT
Objectives: While research has conﬁrmed an association between meta-
bolic syndrome (MetS) and diseases such as heart disease and diabetes,
none of these studies have been conducted in a worksite population.
Because corporations are often the primary payer of health-care costs in
the United States, they have a vested interest in identifying the magnitude
of MetS risk factors in employed populations, and also in knowing
if those risk factors are associated with other health risks or medical
conditions.
Methods: This study identiﬁed the prevalence of MetS risk factors and
self-reported disease in employees (N = 3285) of a manufacturing corpo-
ration who participated in a health risk appraisal and biometric screening
in both 2004 and 2006. Health-care costs, pharmacy costs, and short-term
disability costs were compared for those with and without MetS and
disease.
Results: The prevalence of MetS increased from 2004 to 2006 in this
employed population. Those with MetS were signiﬁcantly more likely to
self-report arthritis, chronic pain, diabetes, heartburn, heart disease, and
stroke. Employees with MetS in 2004 were also signiﬁcantly more likely to
report new cases of arthritis, chronic pain, diabetes, and heart disease in
2006. The costs of those with MetS and disease were 3.66 times greater
than those without MetS and without disease.
Conclusions: MetS is associated with disease and increased costs in this
working population. There is an opportunity for health promotion to
prevent MetS risk factors from progressing to disease status which may
improve vitality for employees, as well as limit the economic impact to the
corporation.
Keywords: diabetes, disease, health-care cost, heart disease, metabolic
syndrome, workplace.
Background
Individuals with metabolic syndrome (MetS) are at increased risk
of morbidity and mortality from a variety of health conditions,
thus making MetS an important trait to recognize and treat. The
deﬁnition of MetS changed over the past decade as researchers
identiﬁed the most critical risk factors. The ﬁrst widely used
deﬁnitions were developed by the World Health Organization [1]
and the National Institutes of Health [2]. Currently, the best
regarded deﬁnition of MetS is that of the American Heart Asso-
ciation and National Heart, Lung and Blood Institute [3], which
has a high utility in determining those at risk. Their deﬁnition
conﬁrmed the value of the Adult Treatment Panel III criteria [2]
with some minor modiﬁcations, making the current standard for
MetS risk criteria based on the following: waist circumference
(102 cm in men, 88 cm in women, or body mass index
[BMI] > 30 kg/m2), triglycerides 150 mg/dl, high-density lipo-
protein [HDL] cholesterol (<40 mg/dl for men or <50 mg/dl for
women, or taking cholesterol medication), blood pressure
(130/85 mmHg or blood pressure medication), and fasting
glucose (100 mg/dl or glucose medication).
Because MetS is characterized by many of the accepted risk
factors of cardiovascular disease (CVD), the former is thought to
be a strong predictor of the latter. In fact, many researchers have
found that the risks of developing CVD (and subsequent death)
are higher among those with MetS compared to those without
the syndrome [4–13]. But, because of the obvious overlap
between MetS and CVD risk factors, some argue that MetS does
not provide any additional information about cardiovascular risk
factors [14]. Others contend that the combined effect of these
risk factors is greater than the sum of its parts, and that knowl-
edge of MetS is helpful and informative in predicting CVD [14].
Individuals with MetS are also at a higher risk of developing
diabetes (ﬁve times higher in one study [14]) compared to those
without MetS [15–17]. Again, this is not unexpected because of
the MetS risk factor of elevated fasting glucose levels, a charac-
teristic of diabetes. Other medical conditions found to be asso-
ciated with MetS include the chronic pain condition ﬁbromyalgia
[18], carpal tunnel syndrome [19–21], asthma [22], and polycys-
tic ovary syndrome [23,24].
None of these previously mentioned studies, however, were
conducted in a worksite population. Corporations are the main
payers of health-care costs in the United States; thus, they have a
more vested interest than corporations in other countries in
identifying the magnitude of MetS risk factors in employed popu-
lations and in knowing if these risks are associated with other
health risks or medical conditions. Many companies offer well-
ness programs to encourage their employees to maintain a
healthy lifestyle, thereby reducing health risks such as those that
deﬁne MetS.
This study identiﬁed the prevalence of MetS risk factors in
employees of a large manufacturing corporation who partici-
pated in a health risk appraisal (HRA) screening in 2004 and
again in 2006. The presence of disease was assessed through
self-report at time 1 in 2004 and at time 2 in 2006 to see if MetS
risk factors were associated with increased rates of disease in an
employed population. Furthermore, health-care costs, pharmacy
costs, and short-term disability (STD) costs were measured
among those who met the criteria for MetS, but did not yet have
an associated disease to see if the risk factors alone are associated
with higher costs.
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Methods
Population and Setting
Employees of a large manufacturing corporation headquartered
in the Midwest were offered an annual HRA and wellness screen-
ing in 2004. The screening achieved extremely high participation
rates (from 85 to 95% of employees) in 2004 to 2006. Of the
3635 individuals who were employed from 2004 to 2006 and
participated in the company’s medical plan, 3285 (90.4%) par-
ticipated in the HRA in 2004 and again in 2006. The majority of
employees during this time period were men (83.0%) and Cau-
casians (89.8%); the average age of the subjects was 40.8 years.
Health Risks
The HRA was an enhanced version of Healthier People, version
4.0 (The Carter Center of Emory University, Atlanta, GA, USA,
1991) including the most recent morbidity and mortality studies
in cooperation with the University of Michigan’s Health Man-
agement Research Center (Ann Arbor, MI, USA). Each partici-
pant who completed the HRA received a personalized report
summarizing his or her health risks, and suggestions for health
improvement directly from the University of Michigan Health
Management Research Center.
The HRA included data from a biometric screening that
utilized venipuncture for blood glucose and lipid panel variables,
and measured height and weight. A third party laboratory was
contracted for the venipuncture procedure. Blood pressure,
fasting glucose, triglycerides, and HDL cholesterol were mea-
sured. Waist circumference was not measured, but BMI was used
as a surrogate. As indicated in the current criteria for MetS, if an
individual has a BMI greater than 30 kg/m2, we can safely
assume that his or her waist circumference exceeds the risk level
[25]. If an individual had any three or more of these risk factors,
he or she was classiﬁed as having MetS.
In addition to asking employees about the presence of 16
biological and lifestyle health risk factors (Table 1), we also
asked the subjects if a doctor had ever told them that they had
any of the following chronic conditions: seasonal allergies,
asthma, arthritis, back pain, cancer (any type), chronic
bronchitis/emphysema, depression, diabetes mellitus, heartburn,
heart disease, high cholesterol, hypertension, irritable bowel syn-
drome, kidney disease, migraine, and stroke. Additionally,
respondents were asked whether they were being treated by a
physician and/or currently taking medications for any reported
conditions. The University of Michigan’s Institutional Review
Board approved this study.
Medical and Pharmacy Claims
Medical and pharmacy claims were available for the study popu-
lation and provided by a third party administrator. The medical
insurance provider and pharmacy beneﬁt manager for this
company provided each claim incurred by each employee in 2004
and 2006 via encrypted transmission. Claims from 2004 and
2006 were summed for each individual each year, and costs were
adjusted for inﬂation to 2006 dollars using the medical consumer
price index [26]. These claims data were then merged with
employee health risk and personnel data.
STD Costs
STD absences were used as a measure of productivity loss.
Absences in 2004 and 2006 were summed for each individual, as
were the STD costs, as provided by the company. At this
company, STD is designed to pay a weekly beneﬁt when an
employee has a nonoccupational illness or injury. This beneﬁt
covers full-time, hourly employees, and is paid at 100%. To
qualify, the employee must be considered disabled and under the
care of a physician. The beneﬁt begins on the eighth consecutive
day for an illness or injury that has not been treated within 72
hours. For accidental injuries that have been treated within 72
hours, the disability beneﬁt would begin the ﬁrst day of the
disability. The maximum duration of STD beneﬁts paid is 26
weeks. If the employee is still disabled after 26 weeks, he or she
is eligible for another 26 weeks of unpaid STD. Long-term dis-
ability coverage is not offered to the majority of employees so
that cost is not included in our study. As with medical and
pharmacy claims, the STD data were merged with the employee
health and personnel information.
Statistical Analyses
The change in prevalence of MetS risk factors from 2004 to 2006
was analyzed using the McNemar chi-square test that was used
to analyze change in a dichotomous measure for paired observa-
tions of the same subjects. The 980 employees with MetS in 2004
were compared to the 2305 employees without MetS to deter-
mine differences in the demographics of the two groups using
t-tests for continuous variables, and chi-square association for
categorical variables. We used multiple linear regression methods
to test the difference in demographics between those with and
those without MetS while controlling for the confounders age
and gender. Prior research has shown that age and gender are
signiﬁcant confounders in the study of MetS [27,28].
We also sought to determine whether or not MetS risk factors
and MetS itself were associated with new cases of disease. For
each MetS risk factor, a multiple logistic regression model was
used to determine if the presence of that risk factor in 2004 was
associated with the incidence of disease in 2006 (arthritis,
chronic pain, diabetes, heartburn, or heart disease) after control-
ling for age and gender. Because of its extremely low prevalence
in this population (only three new cases in 2006), the incidence of
stroke was not modeled.
Table 1 Description of health risks measured by HRA and screening
Risk High-risk cutoff point
Alcohol >14 drinks per week
Blood pressure* 130/85 mmHg (or taking BP medication)
Body mass index* >30.0 kg/m2
Cholesterol >239 mg/dl
Disease Seasonal allergies, asthma, arthritis, back pain, cancer
(any type), chronic bronchitis/emphysema,
depression, diabetes mellitus, heartburn, heart
disease, high cholesterol, hypertension, irritable
bowel syndrome, kidney disease, menopause,
migraine, osteoporosis, or stroke
Use of medication
or drugs to relax
Almost every day or sometimes
HDL cholesterol* <40 for men, <50 for women (or taking cholesterol
medication)
Illness days >5 days in the past year
Glucose* 100 mg/dl (or taking diabetes medication)
Job satisfaction Partly or not satisﬁed
Life satisfaction Partly or not satisﬁed
Perceived health Fair or poor
Physical activity <1 time per week
Safety belt use <100 percent
Smoking Current cigarette smoker
Stress Score >18 (based on a composite score from answers
to marital status, personal loss, life satisfaction,
perception of health, hours of sleep, and social ties)
Triglycerides* 150 mg/dl
*MetS risk factors.
HRA, health risk appraisal.
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Because we have evidence that MetS predicts certain diseases
in an employed population, it was of interest to determine the
costs of individuals with MetS and/or disease. In an employed
population with health-care beneﬁts, medical and pharmaceuti-
cal costs are relevant as are measures of productivity such as
STD. The population was divided into four groups as follows: 1)
those who did not have MetS in 2006 and did not have any of the
ﬁve associated diseases (arthritis, chronic pain, diabetes, heart-
burn, or heart disease); 2) those who had MetS but did not have
any of the ﬁve diseases; 3) those who did not have MetS but did
have one of the ﬁve diseases; and 4) those who had both MetS
and at least one of the ﬁve diseases. We used generalized linear
models to determine signiﬁcant differences in the costs of those
four groups. The ﬁnal analysis examined costs of those four
groups again, but limited the diseases to just diabetes and heart
disease, which are considered to be the most costly diseases
associated with MetS [29]. Unless otherwise noted, the alpha
level for this study was 0.05. All analyses were conducted using
SAS 9.1 software (SAS Institute Inc., Cary, NC).
Results
Prevalence of MetS
The prevalence of MetS risk factors in 2004 and 2006 is shown
in Table 2. The MetS risk factors of glucose, triglycerides, and
hypertension increased in prevalence (P-value <0.01) from 2004
to 2006, as did the percent of employees with MetS (increasing
from 29.8% in 2004 to 32.1% in 2006, P-value = 0.003), and
those who self-reported diabetes (P-value <0.001).
Demographic Differences
Table 3 displays the demographics of those with and without
MetS. Those with MetS were signiﬁcantly older than the other
employees (average age 44.5 vs. 41.3 in 2004, P-value <0.001)
and a greater percentage was male (89.4% vs. 79.8%, P-value
<0.001). Because of these differences, and because age and
gender are known to be signiﬁcant confounders in the analysis of
MetS [27,28], all subsequent analyses controlled for these vari-
ables. There was no difference in the number of employees with
MetS that completed college, had a higher income, were salaried,
unmarried, or Caucasian compared to their counterparts in
the other collected demographics after controlling for age and
gender.
Medical Conditions
Those with and those without MetS in 2004 were compared to
assess differences in the presence of medical conditions in 2004,
after controlling for age and gender (Table 4).
In this employed population, six of the thirteen health con-
ditions were signiﬁcantly more prevalent in the MetS population
compared to other employees: arthritis (odds ratio [OR] 1.48,
95% CI 1.16, 1.90), chronic pain (OR 1.52, 95% CI 1.05, 2.21),
diabetes (OR 5.50, 95% CI 3.46, 8.74), heartburn (OR 1.58,
95% CI 1.25, 1.99), heart disease (OR 2.26, 95% CI 1.42, 3.59),
and stroke (OR 2.25, 95% CI 1.04, 4.62).
MetS Risk Factors and Prediction of Disease
In Table 5, we present the odds ratios and 95% conﬁdence inter-
vals for several multiple logistic regression models.
We found that people who met the risk criteria for obesity
and triglycerides in 2004 were signiﬁcantly more likely to self-
report new cases of arthritis in 2006 (P-value <0.05). These same
risk factors were signiﬁcantly associated with the incidence of
chronic pain in 2006 as well (P-value <0.05). All ﬁve of the risk
factors were associated with the incidence of diabetes, while none
were signiﬁcantly associated with new cases of heartburn.
Finally, hypertension and HDL were associated with the inci-
dence of heart disease 2 years later (P-value <0.05). MetS was
Table 2 Metabolic syndrome risk factors in 2004 and 2006 (N = 3285)
MetS risk factors
2004
(%)
2006
(%)
McNemar’s
statistic P-value
Glucose 31.3 34.4 13.95 0.0002
HDL 32.2 32.6 0.36 0.55
Hypertension 36.7 38.8 6.38 0.01
Obesity 32.1 32.4 0.33 0.57
Triglycerides 43.0 44.3 2.84 0.01
0 MetS risk factors 23.5 21.3
Any 1 MetS risk factor 24.1 24.8
Any 2 MetS risk factors 22.6 21.9
Any 3 MetS risk factors 16.7 17.7
Any 4 MetS risk factors 9.7 10.8
All 5 MetS risk factors 3.4 3.6
MetS (3+ risk factors) 29.8 32.1 8.58 0.003
% reporting heart disease 2.4 2.6 0.53 0.47
% reporting diabetes 3.0 3.7 10.29 0.001
HDL, high-density lipoprotein cholesterol; MetS, metabolic syndrome.
Table 3 Demographics of employees with and without MetS in 2004
who also participated in the HRA in 2006
Without MetS With MetS
P-value*(N = 2,305) (N = 980)
Average age 41.3 years 44.5 years <0.0001
% male 79.8% 89.4% <0.0001
Education level
Some college or less 76.0% 79.9% 0.1765
College graduate or more 24.0% 20.1%
Household income
<$75,000 77.1% 80.7% 0.2425
$75,000 22.9% 19.3%
Hourly employee status 77.2% 83.5% 0.1477
Married 75.9% 78.6% 0.5905
Caucasian 93.6% 92.1% 0.1204
*t-Test for age, chi-square for gender, generalized linear model testing difference in demo-
graphics controlling for age and gender.
MetS, metabolic syndrome; HRA, health risk appraisal.
Table 4 Prevalence of health conditions in 2004 among those with and
without MetS in 2004
Health condition
Without MetS
(N = 2305) (%)
With MetS
(N = 980) (%)
Adjusted OR*
(95% CI)
Allergies 20.5 19.5 0.96 (0.76–1.22)
Arthritis 8.4 14.8 1.48 (1.16–1.90)
Asthma 3.0 3.3 1.11 (0.71–1.75)
Back pain 13.7 13.3 0.98 (0.78–1.24)
Bronchitis/emphysema 0.7 0.5 0.99 (0.87–1.12)
Cancer 2.2 2.7 1.36 (0.89–1.99)
Chronic pain 3.3 5.3 1.52 (1.05–2.21)
Depression 3.3 4.1 1.33 (0.87–1.97)
Diabetes 1.1 7.4 5.50 (3.46–8.74)
Heartburn 9.8 15.3 1.58 (1.25–1.99)
Heart disease 1.6 4.3 2.26 (1.42–3.59)
Migraine 2.9 2.8 1.18 (0.72–1.92)
Stroke 0.2 0.5 2.25 (1.04–4.62)
*Multivariate logistic regression for each disease adjusted for age and gender.
Health conditions in bold font are statistically signiﬁcant (P < 0.05).
MetS, metabolic syndrome.
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signiﬁcantly associated with the prediction of four out of ﬁve
of the conditions (arthritis, chronic pain, diabetes, and heart
disease) with odds ratios ranging from 1.607 for chronic pain to
13.191 for diabetes, after controlling for age and gender.
Figure 1 shows the costs (health care, pharmacy, and STD)
for each of four groups in 2006: those without MetS or any of the
ﬁve associated diseases; those with MetS but no disease; those
without MetS but with a disease; and those with both MetS and
a disease.
The average cost increases from a baseline of $1600 for
employees without MetS and without any of the ﬁve diseases
included here (arthritis, chronic pain, diabetes, heartburn, or
heart disease). The next group of employees, those with MetS but
none of the diseases, had an average cost of $2037. Those
without MetS but at least one of the ﬁve diseases had an average
cost of $4113 which was signiﬁcantly higher than the previous
two groups. Finally, those with both MetS and at least one of
the diseases had the highest costs of $5857 which was signiﬁ-
cantly higher than the other three groups. This ﬁgure shows
the high costs associated with disease among employed
individuals.
The next analysis repeated the previous ﬁgure but limited the
diseases to just diabetes and heart disease. Results are similar to
the results found in Figure 1 with the highest costs occurring in
the last two groups: those without MetS but who have diabetes
or heart disease, and those with both MetS and at least one of
those diseases (Fig. 2).
Discussion
The prevalence of MetS in this employed population is slightly
higher than the prevalence found in nationally representative
studies reporting rates of 23% to 25% [27,28]. Nevertheless, our
study uses the most recent deﬁnitions of MetS which include
people taking medication for glucose, triglycerides, HDL, and/or
hypertension. The prevalence of MetS in this two-time partici-
pant population increased signiﬁcantly from 2004 to 2006. The
authors of another study of the NHANES data sets from 1988 to
1994, and from 1999 to 2000 have also indicated that rates of
MetS are increasing in the United States [30].
As in other studies [27,28], employees who met the criteria
for MetS were signiﬁcantly older and more likely to be male than
those without MetS. Other demographic differences in education
level, income, marital status, and ethnicity were not signiﬁcant
after controlling for age and gender.
The main topic of this study was the relationship between
MetS and disease in a working population. Those with MetS in
2004 were signiﬁcantly more likely to report having arthritis,
chronic pain, diabetes, heartburn, heart disease, and stroke in
2004 compared to those without MetS, after controlling for age
and gender differences. Diabetes and heart disease are obviously
associated, given the overlap between the risk factors for MetS
and those for these two conditions. There is also evidence in the
literature that chronic pain conditions are associated with MetS.
In one study, ﬁbromyalgia was associated with larger waist cir-
Table 5 Odds of incident disease* in 2006 for those with each MetS risk factor in 2004
Risk factor in 2004
Arthritis in 2006
OR (95% CI)
Chronic pain in 2006
OR (95% CI)
Diabetes in 2006
OR (95% CI)
Heartburn in 2006
OR (95% CI)
Heart disease in 2006
OR (95% CI)
Obesity 2.100 1.695 3.831 1.105 1.475
(1.442–3.060) (1.091–2.633) (1.970–7.450) (0.751–1.625) (0.747–2.912)
Hypertension 1.463 1.004 3.829 1.021 2.071
(0.977–2.146) (0.635–1.588) (1.869–7.841) (0.695–1.500) (1.033–4.150)
Glucose 1.261 0.707 15.257 1.169 1.372
(0.849–1.874) (0.996–1.044) (5.834–39.902) (0.789–1.734) (0.685–2.747)
HDL 1.346 1.467 3.048 1.193 2.687
(0.917–1.977) (0.943–2.280) (1.605–5.788) (0.818–1.738) (1.371–5.265)
Triglycerides 1.737 2.621 3.749 1.294 1.559
(1.183–2.551) (1.650–4.164) (1.791–7.848) (0.894–1.873) (0.785–3.097)
MetS 1.999 1.607 13.191 1.172 2.355
(1.359–2.940) (1.021–2.530) (5.428–32.059) (0.789–1.741) (1.187–4.673)
*Logistic regression adjusted for age and gender.
HDL, high density lipoprotein cholesterol; MetS, metabolic syndrome.
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cumference, higher glycosylated hemoglobin and triglyceride
levels, and higher blood pressure [18]. The association found
with heartburn and MetS may simply be an effect of the strong
association between obesity and heartburn. The association with
stroke has not been noted in the literature, but given the similar
risk factors for heart disease and stroke, it is not surprising that
a relationship with MetS would be identiﬁed. The very small
prevalence of stroke in this working population limits the gener-
alizability of these results, however.
Employees with MetS in 2004 were signiﬁcantly more likely
to report new cases of arthritis, chronic pain, diabetes, and heart
disease, but not heartburn. To minimize the level of disease
among employees, organizations should address MetS and its
health risks. Rates of diagnosed diabetes are increasing in the
United States [31,32], and working populations are no excep-
tion. Nevertheless, worksite health management programs have
been shown to be effective in helping “prediabetic” employees
reduce their risks to prevent full-blown diabetes even after 2
years of follow-up [33].
After examining these associations between MetS and
disease, it was appropriate to examine the associated costs
(health care, pharmacy, and STD). The cost of those with MetS
and disease were 3.66 times greater than those without MetS and
without disease. Results indicate that disease is certainly a sig-
niﬁcant factor in determining the costs associated with MetS. All
of those with disease had higher costs than those without disease,
but those with both MetS and disease had the highest cost of any
group. What is most interesting to employers is the fact that
employees with MetS but who had not yet developed one of the
ﬁve health conditions had slightly higher costs, but they were not
yet signiﬁcantly different from the employees without MetS and
without disease.
When the cost analysis was limited to just heart disease and
diabetes, those with MetS and disease had costs ﬁve times higher
than those without MetS and without disease, and four times
higher than those with MetS but who had not yet developed
diabetes or heart disease. Again, the encouraging ﬁnding for
organizations is that the majority (88%) of those with MetS in
this population had not yet developed diabetes or heart disease,
and 67% had not yet developed any of the ﬁve conditions studied
in Figure 1 (arthritis, chronic pain, diabetes, heartburn, or heart
disease). The largest opportunity is in helping these individuals
improve their risks so that those conditions are prevented.
There is an opportunity for health promotion to prevent the
MetS risk factors from progressing to disease status which may
improve vitality for employees, as well as limit the economic
impact to the corporation. An integrated approach to mitigating
the effects of health risks might include several components
[34–37].
• An HRA offered on a regular basis to measure employee
health;
• Analysis of the impact of health on work performance and
all other pertinent outcome measures such as absenteeism,
injuries, and health-care costs;
• Revision of policies and beneﬁts to support work/life
balance;
• Targeted lifestyle and disease management programs to
mitigate risk factors and health conditions;
• Programs which help healthy employees stay healthy, such
as ﬁtness centers
• Evaluation of the work environment and ergonomics;
• Ensuring that employee assistance program providers are
equipped to recognize and treat problems which impact
employee health and on-the-job productivity;
• Enlisting the help of a pharmacy beneﬁt plan to help
manage and improve access to appropriate medication;
• Evaluating coverage for mental health beneﬁts to ensure
that employees have adequate resources to deal with those
types of problems;
• Developing a work environment that discourages working
while ill;
• Applying current programs such as disability case manage-
ment and disease management to help employees with
medical conditions remain productive.
Employers should implement educational and screening pro-
grams for their employees to prevent undiagnosed or misdiag-
nosed illnesses which will allow employees to better manage their
medical conditions. The Wellness Council of America estimates
that an effective, comprehensive program can cost about $100 to
$150 per employee per year [38]. In addition to lower-cost edu-
cational programs, it is also necessary for employers to spend
money on improving employee medical treatment to improve
workplace productivity.
Previous studies have found associations between MetS and
health conditions such as depression [39,40], and kidney disease
[41] which were not identiﬁed in the current analysis. Because of
the particular demographics of this working population (83%
men, with an average age of 40.8 years), it may be unlikely to
detect the association between MetS and depression which has
primarily been studied in female samples. For example, only
3.5% of the study population self-reported depression compared
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to national statistics of major depression affecting 6.6% of the
adult US population in any 1 year [42]. Furthermore, because
this is a population of working adults rather than a patient
population, the rates of certain diseases such as kidney disease
would be small or nonexistent. This is likely because of the
healthy worker effect (HWE). The HWE most often is discussed
in mortality studies because actively employed individuals con-
sistently have a lower mortality rate than the general population
[43]. Nevertheless, it also applies to studies such as this which
examine disease and other health condition prevalence among
employed individuals [44–46].
Limitations
This study is typical of most worksite health promotion studies in
that the design is cross-sectional and retrospective. The ideal
study design (i.e., a randomized, controlled study) is difﬁcult or
impossible to conduct in a worksite population because of the
relationship between employees and employer. Another common
limitation of worksite analyses is that the HRA participants are
not representative of the entire employee population. Because of
the near universal participation rate at this company, the popu-
lation studied is very likely to be representative of the corpora-
tion as a whole although we are assuming that those who did not
participate did so at random and that they represent nonimfor-
mative missing data. The results are unique to this corporation,
however, and similar studies should be conducted in a variety of
worksite industries to see if the ﬁndings are replicated in different
demographic groups.
As was mentioned, waist circumference was not measured, so
BMI was used as a surrogate. The current criteria of MetS states
that if an individual has a BMI greater than 30 kg/m2, we can
safely assume that his or her waist circumference exceeds the risk
level [25]. Nevertheless, it does leave the possibility that indi-
viduals with BMI < 30, but with central adiposity which meets
the waist circumference risk cut point would not be identiﬁed
here. A future study will compare the use of waist circumference
and BMI as risk factors for MetS because the company added
waist circumference to its screening in 2007.
The information on medical conditions in this study relied on
self-reporting of participants. Each individual’s criteria for
reporting a certain condition may not have matched typical
diagnostic criteria for each condition. Previous studies of self-
report data have shown that relying on self-report for medical
conditions can be a valid method [47–49], although in one study
patients reported more conditions than could be veriﬁed in
medical charts [50].
Conclusions
This study provides employers, health-care providers, and public
health professionals with more information about the extent of
MetS and its consequences in working populations. The medical
conditions arthritis, chronic pain, diabetes, heartburn, and heart
disease were signiﬁcantly more prevalent in employees with MetS
than those without MetS. Indeed, individuals with MetS but no
disease in 2004 were more likely to newly report four of those
ﬁve conditions (arthritis, chronic pain, diabetes, and heart
disease) 2 years later. It was unknown whether the diseases
associated with MetS in the general population would also be
found in a working population because of the HWE [51] but it
does appear to be the case.
Moreover, this study highlights the opportunity that is avail-
able to organizations seeking to improve the health of employees.
While employees with MetS and a medical condition had signiﬁ-
cantly higher costs than other employees, the vast majority of
employees with MetS in this study had not yet developed one of
the ﬁve medical conditions studied here, and their costs were not
signiﬁcantly greater than those without MetS. If individuals take
advantage of programs helping them to both maintain their low
risks and reduce their high risks, their odds of experiencing
disease will be reduced. This leads to improved vitality and
quality of life for individuals, and cost avoidance for corpora-
tions in the form of lower health care, pharmacy, and STD costs.
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